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Abstract
Background: Mortality in the first months of antiretroviral therapy (ART) is a significant clinical problem in sub-Saharan
Africa. To date, no post-mortem study has investigated the causes of mortality in these patients.
Methods: HIV-positive adults who died as in-patients at a Johannesburg academic hospital underwent chart-review and
ultrasound-guided needle autopsy for histological and microbiological examination of lung, liver, spleen, kidney, bone
marrow, lymph node, skin and cerebrospinal fluid. A clinico-pathologic committee considered all available data and
adjudicated immediate and contributing causes of death.
Result 4 pre-ART, 15 early-ART (7–90 days), and 10 late-ART (.90 days). Needle
sampling yielded adequate specimen in 100% of kidney, skin, heart and cerebrospinal fluid samples, 97% of livers and lungs,
92% of bone marrows, 87% of spleens and 68% of lymph nodes. Mycobacterial infections were implicated in 69% of deaths
(26 of 27 of these due to M. tuberculosis), bacterial infections in 33%, fungal infections in 21%, neoplasm in 26%, and non-
infectious organ failure in 26%. Immune reconstitution inflammatory syndrome (IRIS) was implicated in 73% of early-ART
deaths. Post-mortem investigations revealed previously undiagnosed causes of death in 49% of cases. Multiple pathologies
were common with 62% of subjects with mycobacterial infection also having at least one other infectious or neoplastic
cause of death.
Conclusions: Needle biopsy was efficient and yielded excellent pathology. The large majority of deaths in all three groups
were caused by M. tuberculosis suggesting an urgent need for improved diagnosis and expedited treatment prior to and
throughout the course of antiretroviral therapy. Complex, unrecognized co-morbidities pose an additional challenge.
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Introduction
As antiretroviral therapy (ART) has been scaled up in sub-
Saharan Africa, attention has focused on the problem of high rates
of mortality in the first months of ART. [1,2] Even when
controlling for the state of immunodeficiency and opportunistic
infections, patients in low-income settings have been shown to
have significantly higher rates of early mortality compared to
patients in high-income settings. [3] The reasons for this excess of
early mortality are poorly understood.[4–7] To date studies
addressing the etiology of these deaths have utilized chart-review
and verbal autopsy, both of which are highly discordant with the
gold standard of pathological autopsy.[8–11] Few pathological
studies of adult patients dying of HIV-related illnesses in
developing countries have been done, and none of these have
included patients being treated with ART.[12–23].
To better understand causes of death in this group, we
conducted a prospective post-mortem study of adults on ART
who died after being admitted to hospital in Johannesburg, South
Africa. A control group consisted of patients with advanced AIDS
who were eligible for ART but had not yet received it. We
ascertained causes of death though needle autopsy, chart review,
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Thirty-nine  adults  were  enrolled:  1 s: and consideration of each case at a standardized clinico-pathologic
conference.
Methods
Ethics Statement
The study was approved by the Ethics Committee of the
University of Witwatersrand and the Institutional Review Board of
Vanderbilt University. Subjects were consented into the study by
one of two methods. Competent and willing subjects provided
written consent for enrollment in the event of their death. After the
death of disoriented or unconscious subjects, the next of kin
provided written consent for participation. All clinical investiga-
tions were conducted according to the principles expressed in the
Declaration of Helsinki.
Setting and Subject Eligibility
Data were prospectively collected at Charlotte Makexe
Johannesburg Academic Hospital, a 1088-bed, public, tertiary
hospital located in central Johannesburg with a free ART program
of over 3000 patients. At the time of the study, South African
national guidelines allowed for ART initiation in patients with
CD4 cell count ,200 cells/mm
3. In 2009, the HIV prevalence
rate for Johannesburg’s province was 11.3% of the adult
population; the reporting rate for tuberculosis cases was
469.9 per 100,000 per annum. [24].
Eligibility criteria for this study were: age .18 years, HIV-
positive, either on ART or eligible for ART, and death occurring
on one of the medical wards. Exclusion criteria were pregnancy
and a history of defaulting or restarting ART.
Study Procedures
Record review of pre-mortem data. A chart review was
undertaken for each enrolled subject. Variables collected included:
history of HIV and ART, history of tuberculosis (TB) and
treatment, other comorbidities and opportunistic infections,
clinical features of the presenting illness, and all radiology and
laboratory results from hospital admission until the time of death.
Needle autopsy. The needle autopsy method was chosen
because it can identify a pathogen in a significant proportion of
HIV deaths and is faster, cheaper, and more acceptable to families
than conventional autopsy. [25–27] As soon as possible after
death, investigators aspirated cerebrospinal fluid (CSF) and
performed standardized needle biopsies of the lungs (focusing on
areas of abnormality on pre-mortem chest x-ray), liver, spleen,
kidneys, and bone marrow. Additional biopsies of the heart, skin,
lymph nodes and any accessible masses were obtained when pre-
or post-mortem abnormalities were present. An ultrasound was
used to locate the kidneys, spleen and heart. Other organs were
located by external anatomical landmarks. Half-centimeter
incisions were made in the skin overlying each biopsy site and
closed with single sutures to achieve minimal cosmetic disturbance.
Solid organ biopsies were obtained with 14-gauge core biopsy
needles, bone marrow trephines with 14-gauge Jamshidi needles,
CSF aspirated with 18-gauge syringes, and skin biopsied with
standard punch tools. Multiple core biopsies (2 to 4 per skin
incision) were obtained from the solid organs (lung, liver, spleen
and kidney); biopsy specimens were, on average, 1.6 mm in
diameter and ranged from 4–20 mm in length. Needle autopsies
were performed by two investigators (E.B.W. and G.J.S.).
Histologic investigations. Tissue cores from each organ
were preserved in formalin, embedded in paraffin and stained with
Hematoxylin-eosin, Ziehl-Neelsen (ZN) for acid fast organisms,
and Brown-Hopps modified tissue gram stain. Lung cores were
stained with Grocott’s Methanamine Silver for fungi. Cytomeg-
alovirus immunoperoxidase staining was performed when char-
acteristic viral inclusions were noted. Additional immunohisto-
chemical and special stains were performed as needed. Cytological
examination was performed on CSF. Tissue processing and stains
were performed by the National Health Laboratory Service with
all interpretation performed by the study pathologist (T.O.).
Microbiologic investigations. Tissue cores were obtained
using sterile technique and transported for same day processing.
Specimens were subjected to aerobic and anaerobic bacterial
cultures (lung, spleen); fungal culture (lung, spleen and CSF);
mycobacterial culture (lung, spleen, liver, bone marrow, lymph
node and CSF) and cryptococcal antigen testing (CSF). Antibiotic
sensitivities were performed for positive bacterial cultures.
Mycobacterial cultures were performed using the Bactec MGIT
system (Becton Dickinson, New Jersey, USA) followed by species
identification using the GenoType Mycobacterium CM Assay
(Hain Lifesciences, Nehren, Germany) at the Johannesburg
Tuberculosis Reference Laboratory. Real-time PCR-based Light-
Cycler Mycobacterium detection assay (Roche Diagnostics,
Germany) was performed on lung, liver, lymph node and CSF;
specimens with sufficient leftover volume were also tested in the
Xpert MTB/RIF PCR (Cepheid, California, USA) assay. Details
of tissue preparation for the PCR assays have been published
separately. [28].
Clinico-pathologic conferences. A committee of experi-
enced infectious disease, pulmonary and pathology specialists from
South Africa and the United States (C.F., D.M., N.M., R.O.,
T.O., G.S., W.D.F.V., E.W.) met at three clinico-pathologic
conferences to adjudicate the immediate and contributing causes
of death for each subject. The immediate cause of death was
defined as the disease or condition directly leading to death
whereas the contributing causes of death included other diseases or
conditions believed to have contributed to the fatal outcome. [29]
The committee reviewed the clinical history, pre-mortem inves-
tigations, post-mortem microbiology and post-mortem histology of
each subject. A pre-designated rule dictated the interpretation of
post-mortem bacterial and fungal cultures: an organism was
considered pathologic only if 1) the same organism was cultured in
pre-mortem culture or if 2) the affected organ showed appropriate
vital inflammation on histology.
Categorization of causes of death. Causes of death were
categorized as bacterial, fungal, mycobacterial, viral (non-HIV),
neoplastic and non-infectious organ failure. Immune Reconstitu-
tion Inflammatory Syndrome (IRIS) was defined as worsening of
disease with signs of clinically significant inflammation within 90
days of ART initiation despite appropriate treatment. TB IRIS
was further defined as either paradoxical (known TB diagnosis
with initial improvement on anti-tubercular therapy and subse-
quent paradoxical worsening) or unmasking (diagnosis of inflam-
matory TB within 90 days of ART initiation in a patient
previously free of TB) in accordance with published consensus
definitions. [30] Causes of death were defined as unsuspected by
clinicians if they were revealed solely by the post-mortem
investigations. Subjects in whom a cause of death remained
imprecisely understood due to limitations of the post-mortem
technique (ie. lack of sampling of the gastrointestinal tract or brain)
were also recorded.
Analysis
Baseline characteristics and the proportion of deaths attribut-
able to each category were calculated overall and in three pre-
planned sub-groups: pre-ART (,7 days of ART at the time of
death), early-ART mortality (7–90 days of ART at the time of
Causes of Death of Antiretroviral Therapy
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death). One-way analysis of variance and Fisher’s exact test were
used to determine association between baseline characteristics and
categories of mortality in these three groups. The sample size was
dictated by the available budget.
Results
Pre-mortem Characteristics
From January – December 2009, 39 HIV-infected adults were
enrolled. Six (15%) consented themselves prior to death; 33 (85%)
were consented by family members after death. Half were women,
median age was 36 years (IQR 32–40) and median CD4 count was
50 cells/mm
3 (IQR 27–154, Table 1). Median length of
hospitalization was 5 days (IQR 2–13) and 3 subjects received
intensive care. Thirteen (33%) had received a diagnosis of
tuberculosis and were on anti-tuberculosis therapy at the time of
admission. Fourteen (36%) were on sulfamethoxazole-trimetho-
prim prophylaxis at the time of admission. Thirty-five (90%)
received broad-spectrum antibiotics (most commonly amoxicillin/
clavulanic acid, ceftriaxone, or pipercillin/tazobactam) and 23
(59%) received steroids during hospitalization (most often initiated
empirically due to concern for hypoaldrenalism, P. jerovici
pneumonia or IRIS).
Twelve subjects were ART naı ¨ve and 2 had received ,7 days of
ART at the time of death; in this pre-ART group the median CD4
cell count was 49 cells/mm
3 (IQR 18–111). Twenty-five subjects
received .7 days of ART at the time of death; 15 were
categorized as early-ART mortality with median duration of
ART 32 days (IQR 16–50) and median CD4 cell count 61 cells/
mm
3 (IQR 46–154) and 10 were categorized as late-ART
mortality with median duration of ART 326 days (IQR 148–
531) and median CD4 cell count 43 cells/mm
3 (IQR 27–175).
Reported CD4 cell counts were those measured most proximally
to death. Details of the antiretroviral regimen were available for 21
subjects, all of whom were on two nucleoside reverse transcriptase-
inhibitors (11 stavudine/lamivudine, 5 didanosine/lamivudine, 5
tenofovir/lamivudine) and one non-nucleoside reverse transcrip-
tase inhibitor (19 efavirenz, 2 nevirapine).
Performance of the Needle Autopsy and Microbiologic
Results
Median time from death to needle autopsy was 25 hours (range
5–55). The quality of each sample was assessed at histological
examination and categorized as adequate (containing representa-
tive target tissue) or missed (Table 2). Adequate samples were
obtained from the majority of biopsies: kidney (100%), skin
(100%), heart (100%), CSF (100%), lung (97%), liver (97%), bone
marrow (92%), spleen (87%), lymph node (68%). Bacterial cultures
of the lung were pathogenic in 26% and contaminated in 33% of
samples; in the spleen bacterial culture was pathogenic in 18% and
contaminated in 15%. Pathogenic bacteria cultured from lung and
spleen were E. coli (isolated in 8 cultures), Acinetobacter sp. (3),
Enterobacter sp. (3), Klebsiella sp. (3), Clostridium sp. (2), Proteus sp. (2),
and Salmonella sp.(1). Mycobacterial cultures were positive in 24%
of livers, 23% of spleen, 19% of lung, 16% of lymph node, 15% of
bone marrow and 10% of CSF samples. Mycobacterial cultures
were positive in 16 subjects; with the organism identified as M.
tuberculosis in 13, M. avium in 1, and unable to be further speciated
due to contamination in 2. M. tuberculosis was identified by PCR in
the tissues of 5 additional subjects. Fungal cultures had low rates of
positivity: 8% in CSF, 8% in spleen and 3% in lung. The
pathogenic fungi cultured from CSF, spleen and lung were C.
neoformans (isolated in 6 cultures) and C. albicans (1).
Causes of Death: as Determined by the Clinico-
pathologic Committee
Mycobacterial infection, confirmed microbiologically (in 21
cases) and/or histologically (in 26 cases), was the leading cause of
death in the pre-ART (57%, 8/14) and on-ART groups (76%, 19/
25) and contributed to the large majority of early-ART deaths
(87%, 13/15, Table 3). Of the 27 cases of mycobacterial infection,
25 cases were determined to be due to M. tuberculosis,1t oM. avium;
and 1 to a mycobacterial infection that could not be specified. All
mycobacterial deaths had evidence of disseminated infection
(microbiological and histologic evidence detailed in Table 4). In
those in whom mycobacterial infection caused death, it was the
immediate cause of death in 56% (15/27). Of the 26 subjects with
non-M. avium mycobacterial infection, 10 (37%) had been treated
Table 1. Pre-mortem characteristics of the study population.
All deaths Pre-ART deaths Early-ART deaths Late-ART deaths p-value
n=39 n=14 n=15 n=10
Female, n (%) 19 (49%) 5 (36%) 8 (53%) 6 (60%) 0.47
Age in years, median (IQR) 36 (32–40) 37.5 (33–40) 33 (30–39) 36 (32–44) 0.30
CD4 cells/mm
3a, median (IQR) 50 (27–154) 49 (18–111) 61 (46–154) 43 (27–175) 0.50
Days in hospital, median (IQR) 5 (2–13) 8 (2–15) 3 (2–11) 3.5 (1–9) 0.48
Days of ART, median (IQR) 32 (16–50) 326 (148–531)
On TB treatment at admission, n (%) 13 (33%) 3 (21%) 7 (47%) 3 (30%) 0.36
On sulfamethoxazole- trimethoprim prophylaxis
at admission, n (%)
14 (36%) 6 (43%) 5 (33%) 3 (30%) 0.84
Received broad-spectrum antibiotics during
hospitalization, n (%)
35 (90%) 14 (100%) 14 (93%) 7 (70%) 0.07
Received steroids during hospitalization, n (%) 23 (59%) 9 (64%) 9 (60%) 5 (50%) 0.85
Categorized by duration of antiretroviral therapy (ART) at the time of death. Pre-ART deaths occurred in subjects who were HIV-positive and eligible for ART but had not
yet received it (CD4 cell count ,200 cells/mm
3) or those who had received ,7 days of ART. Early ART deaths occurred between 7–90 days of ART. Late ART deaths
occurred after .90 days of ART.
aCD4 count measured most recently prior to death.
doi:10.1371/journal.pone.0047542.t001
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started on TB therapy during hospitalization and 9 (33%) were
never initiated on TB therapy. Disseminated mycobacterial
infection was revealed as a previously unsuspected cause of death
at post-mortem in 9 subjects (6 in the early-ART mortality group).
Bacterial infections were the second highest overall cause of
death (33%, 13/39); with pneumonia and sepsis as the most
common manifestations (6 and 7 cases, respectively) and two cases
of C. difficile colitis. Pneumonia and sepsis were both most often
due to gram-negative enterobacteriaceae (7 cases) with 3 cases of
noscomial Acinetobacter sp. pneumonia. Fungal infections contrib-
uted to 21% (8/39) of deaths overall (4 C. neoformans,2P. jiroveci,1
C. albicans, and 1 invasive aspergillosis). The rates of bacterial and
fungal causes of death were comparable in the pre-ART group
(36% and 21% respectively) and early-ART group (40% and
27%), with a trend towards lower rates in the late-ART group
(20% and 10%). Viral infections (other than HIV) contributed to
8% (3/39) of overall deaths (2 Hepatitis B, 1 cytomegalovirus
pneumonitis). Schistosomiasis contributed to 1 death. Neoplasm
contributed to 21% (3/14) of pre-ART deaths, 20% (3/15) of
early-ART deaths and 40% (4/10) of late ART deaths (6 Kaposi’s
sarcoma, 2 large B-cell lymphomas, 1 Hodgkins lymphoma, 1
metastatic carcinoma of unknown primary). Non-infectious organ
failure contributed to 26% (10/39) of deaths (4 renal failure, 3
cardiac failure, 2 neurologic, 1 pulmonary embolus). Causes of
death that had not been suspected clinically were revealed by the
post-mortem technique in half of the cases (49%, 19/39). Causes
of death that the committee determined to be insufficiently
explained by the post-mortem technique were identified in 13%
(5/39–2 abdominal processes and 3 brain processes, Table 4).
Infectious and neoplastic causes of death were frequently
concurrent. Of the 27 subjects with disseminated mycobacterial
infection as a cause of death, 62% (17/39) had at least one other
infectious or neoplastic cause of death: bacterial infection (6), viral
infection (2), fungal infection (2) and neoplasm (2). Three subjects
had concurrent neoplasm, bacterial and mycobacterial infections;
1 had concurrent bacterial, fungal and mycobacterial infections,
and 1 had concurrent neoplasm, bacterial, viral, parasitic, and
mycobacterial infections.
IRIS was implicated in 73% (11/15) of early-ART deaths. IRIS
was attributed to mycobacterial infection in 8 cases (6 M.
tuberculosis,1M. avium, 1 unspecified mycobacterium), Kaposi
sarcoma in 1 case, and both M. tuberculosis and C. neoformans in 2
cases. The median CD4 cell count for all IRIS cases was 77 cells/
mm
3 (IQR 46–154); and median duration of ART was 32 days
(IQR 17–37). Of the 8 TB IRIS cases, 4 were unmasking IRIS and
4 paradoxical IRIS. The unmasking TB IRIS cases were all
characterized by necrotizing granulomatous inflammation in
multiple organs and positive M. tuberculosis tissue cultures
(Table 4). The paradoxical TB IRIS cases had a median duration
of antituberculosis therapy of 109 days (IQR 80–144). Two
paradoxical TB IRIS cases displayed non-necrotizing granuloma-
tous inflammation (ZN negative) and 2 displayed necrotizing
granulomatous inflammation (ZN positive). Three of 4 cases had
negative TB cultures and the only positive TB culture in this group
was from CSF.
Discussion
To our knowledge this is the first study from any developing
country to use post-mortem investigations to report the causes of
mortality for HIV patients on ART. The needle autopsy protocol
described here was efficient and resulted in high histologic and
mycobacteriologic yield. Tuberculosis was the leading cause of
T
a
b
l
e
2
.
T
h
e
y
i
e
l
d
o
f
n
e
e
d
l
e
a
u
t
o
p
s
y
b
y
s
i
t
e
a
n
d
i
n
v
e
s
t
i
g
a
t
i
o
n
.
S
i
t
e
L
u
n
g
L
i
v
e
r
S
p
l
e
e
n
K
i
d
n
e
y
B
o
n
e
M
a
r
r
o
w
L
y
m
p
h
N
o
d
e
S
k
i
n
H
e
a
r
t
C
S
F
M
e
t
h
o
d
o
f
s
a
m
p
l
i
n
g
b
l
i
n
d
c
o
r
e
b
l
i
n
d
c
o
r
e
u
l
t
r
a
s
o
u
n
d
c
o
r
e
u
l
t
r
a
s
o
u
n
d
c
o
r
e
t
r
e
p
h
i
n
e
b
l
i
n
d
c
o
r
e
p
u
n
c
h
u
l
t
r
a
s
o
u
n
d
c
o
r
e
a
s
p
i
r
a
t
i
o
n
A
t
t
e
m
p
t
e
d
s
a
m
p
l
e
s
,
n
(
a
d
e
q
u
a
t
e
f
o
r
a
n
a
l
y
s
i
s
,
m
i
s
s
e
d
)
3
9
(
3
8
,
1
)
3
9
(
3
8
,
1
)
3
9
(
3
4
,
5
)
3
9
(
3
9
,
0
)
3
9
(
3
6
,
3
)
1
9
a
(
1
4
,
5
)
2
0
b
(
2
0
,
0
)
3
c
(
3
,
0
)
3
9
(
3
9
,
0
)
B
a
c
t
e
r
i
a
l
c
u
l
t
u
r
e
,
n
(
p
o
s
i
t
i
v
e
,
n
e
g
a
t
i
v
e
,
c
o
n
t
a
m
i
n
a
t
e
d
)
3
9
(
1
0
,
1
6
,
1
3
)
3
9
(
6
,
2
6
,
7
)
F
u
n
g
a
l
c
u
l
t
u
r
e
,
n
(
p
o
s
i
t
i
v
e
,
n
e
g
a
t
i
v
e
,
c
o
n
t
a
m
i
n
a
t
e
d
)
3
7
(
1
,
2
5
,
1
2
)
3
9
(
3
,
3
3
,
3
)
3
7
(
3
,
3
3
,
1
)
M
y
c
o
b
a
c
t
e
r
i
a
l
c
u
l
t
u
r
e
,
n
(
p
o
s
i
t
i
v
e
,
n
e
g
a
t
i
v
e
,
c
o
n
t
a
m
i
n
a
t
e
d
)
3
6
(
7
,
2
1
,
8
)
3
8
(
9
,
2
4
,
5
)
3
9
(
9
,
2
6
,
4
)
3
9
(
6
,
3
6
,
7
)
1
9
(
3
,
1
3
,
3
)
3
9
(
4
,
3
2
,
3
)
C
r
y
p
t
o
c
o
c
c
a
l
a
n
t
i
g
e
n
,
n
(
p
o
s
i
t
i
v
e
,
n
e
g
a
t
i
v
e
)
2
7
(
3
,
2
4
)
C
y
t
o
l
o
g
y
,
n
(
p
o
s
i
t
i
v
e
f
o
r
n
e
o
p
l
a
s
m
,
n
e
g
a
t
i
v
e
)
3
0
(
0
,
3
0
)
a
L
y
m
p
h
n
o
d
e
s
w
e
r
e
b
i
o
p
s
i
e
d
i
n
p
a
t
i
e
n
t
s
w
i
t
h
p
a
l
p
a
b
l
e
l
y
m
p
h
a
d
e
n
o
p
a
t
h
y
o
n
p
o
s
t
-
m
o
r
t
e
m
e
x
a
m
.
b
S
k
i
n
b
i
o
p
s
y
w
a
s
p
e
r
f
o
r
m
e
d
i
n
p
a
t
i
e
n
t
s
w
i
t
h
r
a
s
h
o
n
p
o
s
t
-
m
o
r
t
e
m
e
x
a
m
.
c
H
e
a
r
t
w
a
s
b
i
o
p
s
i
e
d
i
f
p
r
e
-
m
o
r
t
e
m
h
i
s
t
o
r
y
w
a
s
s
u
g
g
e
s
t
i
v
e
o
f
c
a
r
d
i
a
c
c
a
u
s
e
o
f
d
e
a
t
h
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
4
7
5
4
2
.
t
0
0
2
Causes of Death of Antiretroviral Therapy
PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e47542death regardless of ART status and was particularly high in
subjects dying in the first 3 months of ART, in whom 87% had
disseminated mycobacterial infection as an immediate or contrib-
uting cause of death. Multiple concurrent pathologies were
common; 62% of subjects dying from mycobacterial infection
had at least one additional infectious or neoplastic cause of death.
IRIS contributed to 73% of early-ART mortality. Post-mortem
investigations revealed clinically unrecognized causes of death in
half of the subjects.
The finding that tuberculosis is the leading overall cause of
death is consistent with prior autopsy studies of HIV patients from
sub-Saharan Africa and India in the pre-ART era. In a 2010
meta-analysis of all autopsy studies of HIV patients from sub-
Saharan Africa over the last two decades, tuberculosis was
considered a cause of death in 32–45% of 593 autopsied adults.
[11,13,18,20,31] In a series of 236 HIV-positive, ART-naı ¨ve
patients from Mumbai, tuberculosis was implicated in 63% of
deaths. [17] Our finding that every case of tuberculosis was
disseminated beyond the lungs supports the finding by Martinson
et al. that in their largely HIV infected, ART-naı ¨ve subjects, 97%
of those with tuberculosis had evidence of disseminated disease
during complete autopsy. [12] Our data on the importance of
tuberculosis also support the conclusions of prior studies of cause-
specific mortality of HIV patients on ART in low-income settings
which used non-pathologic evidence from chart reviews and verbal
autopsies. Tuberculosis is consistently among the leading causes of
death in these studies, implicated in 16–18% of deaths in studies
from Haiti, Senegal and Uganda and in 19–44% of deaths from
two South African cohorts.[8,9,32–35] The higher number of
deaths attributed to tuberculosis in our study is likely explained by
the contribution of post-mortem investigations which revealed that
a third of microbiologically and/or histologically-proven tubercu-
losis infections were clinically unsuspected at the time of death.
Our finding that IRIS contributed to over 70% of early-ART
deaths highlights the importance and deadly potential of severe
IRIS; in cohort studies based at ART clinics the condition has
been described as usually self-limited and infrequently fatal.
[36,37] In cohort studies from Uganda and South Africa that have
determined cause of death through chart-review and verbal
autopsy, IRIS has been implicated in 7% of early-ART deaths and
17% of all ART-deaths respectively. [8,33] Fatal IRIS has been
reported, especially in central nervous system infections.[38–40]
Although our study setting at a tertiary referral hospital may have
influenced our findings, our high rate is supported by detailed
clinicopathological data. The fatal cases described here challenge
certain characteristics that have been used to define IRIS. In the
consensus definition, the presence of another infection excludes
IRIS [30]; however case E26 in this study demonstrates
convincing evidence of paradoxical central nervous system TB
IRIS with a simultaneous nosocomial bacterial pneumonia. In
case E33, exuberant necrotizing granulomatous inflammation of
multiple organs convinced the clinico-pathologic committee to
diagnose concomitant paradoxical TB IRIS and unmasking
cryptococcal IRIS (Figure 1).
This study does have a number of limitations. Small sample-size
limited the ability of this study to find significant differences
between pre-ART, early-ART and late-ART mortality and to
pick-up low frequency causes of death. The pathology reported
here is a minimum estimate as the needle autopsy was limited to
sampled organs and likely missed important pathology in non-
sampled organs (particularly in the abdomen/pelvis and cranium);
similarly, areas of focal pathology within biopsied organs may have
been missed. A study comparing results of needle and conven-
tional autopsies found a concordance on primary cause of death in
67% of cases. [41] The predominance of gram-negative organisms
in pre- and post-mortem cultures may be due to the translocation
of enteric organisms across HIV-damaged gut mucosa and
nosocomial pneumonias, but the striking lack of gram-positive
cultures is most likely the result of pre-mortem broad-spectrum
antibiotics and may have caused us to underestimate the
contribution of pathogens like S. aureus and S. pneumonia to
bacterial causes of death. Measuring HIV viral load at the time of
death would have been helpful in determining adherence to and
effectiveness of ART. This study may have overestimated the
Table 3. Causes of death by category.
All deaths Pre-ART deaths Early-ART deaths Late-ART deaths p-value
n=39 n=14 n=15 n=10
Causes of death by category
a
Mycobacterial, n (%) 27 (69%) 8 (57%) 13 (87%) 6 (60%) 0.16
Bacterial, n (%) 13 (33%) 5 (36%) 6 (40%) 2 (20%) 0.45
Fungal, n (%) 8 (21%) 3 (21%) 4 (27%) 1 (10%) 0.79
Viral (non-HIV), n (%) 3 (8%) 2 (14%) 0 (0%) 1 (10%) 0.35
Neoplasm, n (%) 10 (26%) 3 (21%) 3 (20%) 4 (40%) 0.58
Organ dysfunction
b, n (%) 10 (26%) 1 (7%) 5 (33%) 4 (40%) 0.13
Immune reconstitution inflammatory syndrome, n
(%)
11 (28%) 11 (73%)
Unsuspected by clinicians at time of death
c, n (%)19 (49%) 7 (50%) 8 (53%) 4 (40%) 0.85
Not satisfactorily explained by post-mortem
technique, n (%)
5 (13%) 4 (29%) 1 (7%) 0 (0%) 0.13
Categorized by duration of antiretroviral therapy (ART) at the time of death. Pre-ART deaths occurred in subjects who were HIV-positive and eligible for ART but had not
yet received it (CD4 cell count ,200 cells/mm
3) or those who had received ,7 days of ART. Early ART deaths occured between 7–90 days of ART. Late ART deaths
occurred after .90 days of ART.
aAll causes of death (immediate and contributing) are included and each subject may have multiple causes of death.
bNon-infectious organ dysfunction, ie. pulmonary embolus or end stage renal disease.
cAt least one cause of death was revealed only through the post-mortem investigations.
doi:10.1371/journal.pone.0047542.t003
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PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e47542impact of IRIS due to miscategorization of overwhelming
infections as unmasking IRIS; use of a prospective study design
with serial measurements of CD4 cell count and HIV viral load
might have more accurately made this distinction. We did not do
mycobacterial drug-susceptibility testing which would also have
helped clarify whether deteriorations after ART were due to IRIS
Figure 1. Simultaneous C. neoformans pneumonia and paradoxical M. tuberculosis Immune Reconstitution Inflammatory Syndrome
(IRIS). At the time of death, this patient (E33) had been on anti-tuberculosis therapy for pulmonary tuberculosis for 5 months (with good response to
treatment) and antiretroviral therapy for 1 month. Histologic sections demonstrate (a) suppurative consolidation of the lungs with (b) cryptococcal
organisms apparent on Grocott’s Methanamine Silver (GMS) stain. Kidney (c) and spleen (d) demonstrate well formed necrotizing granulomatous
inflammation, with negative Ziehl-Neelsen and GMS stains for organisms; these were thought to represent an exuberant inflammatory response due
to paradoxical TB IRIS.
doi:10.1371/journal.pone.0047542.g001
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PLOS ONE | www.plosone.org 9 October 2012 | Volume 7 | Issue 10 | e47542or drug-resistant disease. [42,43].The setting of our study in an
urban tertiary referral hospital with access to advanced diagnostic
procedures and intensive care facilities may limit the application of
our findings to other settings.
The standardized needle autopsy described here was minimally
mutilating, was efficient to perform, did not delay burial and had a
very high pathological yield. While there is still a need for
complete autopsies, in situations that preclude them a version of
this needle autopsy protocol, perhaps modified to include brain
and abdomen/pelvis sampling, has the potential to provide crucial
post-mortem data.
Our findings demonstrate that tuberculosis is the major killer of
HIV patients in sub-Saharan Africa, that it is frequently
unrecognized and often accompanied by concurrent infections
or neoplasms. Because simultaneous complex pathologies contrib-
ute to mortality, additional diagnoses should be sought for patients
not clinically improving despite receiving treatment for known
diagnoses. Additional study of the pathogenesis of and therapeutics
for severe IRIS is needed. The development of a comprehensive
response to the diagnosis and prevention of tuberculosis prior to
and throughout the course of antiretroviral therapy is likely to
have an enormous life-saving potential.
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